Marin Voice: GLP-1s are revolutionizing weight management, diabetes care

When I tell people I direct clinical research studies, I often encounter surprise. “Aren’t you a physician?” they ask.

It seems many don’t fully grasp the crucial role of clinical trials in advancing medical care. We all benefit from medications, yet few realize the rigorous research that precedes drug availability, and fewer still are aware of opportunities to participate in clinical trials right here in Marin. Meticulous clinical studies are essential to confirm scientific hypotheses and translate promising laboratory findings into safe and effective treatments for patients.

Take GLP-1 (glucagon-like peptide-1) medications, for example. These “wonder drugs” are revolutionizing how we treat obesity, diabetes, heart and kidney diseases. As an endocrinologist and researcher in Marin since the mid-1980s, I’ve been fortunate to participate firsthand in the journey of GLP-1s from early research to their current global impact in my role as a medical director and primary investigator at NorCal Medical Research.

The discovery that there were hormones produced in the normal gut that regulate blood sugar after eating was a pivotal moment some 40 years ago. Clinical researchers later developed the GLP-1 drugs to be lookalike compounds that could occupy receptors for the naturally occurring GLP hormones and mimic their effects. They could lower blood glucose after meals by slowing gastrointestinal activity, by reducing stored glucose release and by stimulating insulin.

But the unanticipated effects of the GLP-1s were those in the brain. Amazingly, it reduced appetite, caused sensations of fullness and, consequently, led to weight loss. Early research confirmed GLP-1s could lower blood sugar levels and hemoglobin A1C in people with type 2 diabetes, but many additional benefits have emerged recently from clinical trials in persons with and without diabetes including reduced risk of heart and kidney disease, and even improvements in sleep apnea.

These medications have transformed the treatment landscape offering hope to millions. It has the potential to markedly reduce all-cause mortality.

The remarkable success of GLP-1s is a testament to the power of rigorous clinical research. These studies, involving thousands of participants, have provided invaluable insights into the safety, efficacy and long-term impact of the GLP-1 and related weight-loss medications. They have led to a much deeper understanding of what causes these conditions.

My group has been actively involved in this exciting field from the beginning, conducting numerous clinical trials and contributing to our understanding of GLP-1s and their potential.

While current GLP-1s have shown remarkable promise, ongoing research continues to explore:

• Combining GLP-1s with other medications to enhance effectiveness and reduce side effects

• Developing more convenient oral and injectable medications to improve patient experience

• Investigating the potential of GLP-1s to treat other conditions

• Monitoring long-term safety and identifying potential side effects.

Participating in a clinical trial offers opportunities to access cutting-edge treatments, contribute to medical advancement and receive highly personalized and confidential care.

Other benefits of participation may include some surprising positives: access to free investigational medications; comprehensive medical monitoring at no cost; lifestyle, exercise and dietary counseling; reimbursement for time and travel; and satisfaction of contributing to improving health care for future generations.

GLP-1 research has shown the previous advice of the past (eat fewer calories and exercise more)  is inadequate for treating significant weight disorders in most people. Regaining weight lost by “dieting” and overexercising alone is frustrating for patients. Obesity is not patient failure or “noncompliance,” but a complex chronic medical disease which can now be treated more successfully by addressing underlying imbalances in the GLP-1 and related gut-hormone levels, along with medically monitored lifestyle improvements.

Kudos to the thousands of scientists, researchers, medical workers, monitoring institutions, pharmaceutical companies and patients for pursuing this transformative work.

Dr. Linda M. Gaudiani is medical director of NorCal Medical Research, Inc., a private medical research center in Greenbrae. Learn more at NorCalMedicalResearch.com. The information presented in this commentary is for general knowledge and educational purposes only. It does not constitute medical advice.